Search Result
Results for "
Lysophosphatidylcholines
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
9
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P1410
-
|
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
-
- HY-139414
-
|
|
Interleukin Related
p38 MAPK
ERK
Apoptosis
|
Inflammation/Immunology
|
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
-
-
- HY-125783
-
-
-
- HY-N9410
-
|
1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC(18:2/0:0); LysoPC(18:2)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .
|
-
-
- HY-P1410A
-
|
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 TFA also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 TFA is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
-
- HY-125771
-
|
18:0 Lyso-PC; LPC(18:0)
|
Endogenous Metabolite
HDAC
STAT
Apoptosis
|
Cancer
|
|
1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
|
-
-
- HY-177475
-
|
1-Arachidonoyl-sn-glycero-3-phosphocholine
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
LysoPC 20:4 (20:4) (1-Arachidonoyl-sn-glycero-3-phosphocholine) is a serum metabolite. LysoPC 20:4 (20:4) decreases in tumor-bearing mice, but the reduction is not significant. LysoPC (20:4) can be used in cancer and obesity-related research .
|
-
-
- HY-158790
-
|
|
Ferroptosis
|
Cancer
|
|
(R)-HTS-3 is an lysophosphatidylcholine acyltransferase 3 (LPCAT3) inhibitor, with an IC50 of 0.09 μM. (R)-HTS-3 suppresses the C20:4 content of PE, PC, and PS, while promoting a correspondingelevation in C22:4 phospholipids and a paradoxical increase in C20:4 phosphatidylinositol (PI) lipids .
|
-
-
- HY-112825
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT)1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively). 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
|
-
-
- HY-W414591
-
|
1-Lauroyl-2-hydroxy-sn-glycero-3-phosphatidylcholine; 12:0 Lyso PC
|
Drug Derivative
|
Metabolic Disease
|
|
L-alpha-lysophosphatidylcholine, lauroyl (1-Lauroyl-2-hydroxy-sn-glycero-3-phosphatidylcholine) is an ester product.
|
-
-
- HY-113470
-
-
-
- HY-154830
-
|
1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine; 19:0 Lyso PC
|
Liposome
Interleukin Related
|
Others
|
|
Lysophosphatidylcholine C19:0 (1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine) is an acyl chain lipid. Lysophosphatidylcholine C19:0 increases IL-1beta secretion .
|
-
-
- HY-W329357
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .
|
-
-
- HY-N9410S
-
|
1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC-d9
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
|
Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary
|
-
-
- HY-12812
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
Cancer
|
|
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .
|
-
-
- HY-125783S1
-
-
-
- HY-126233
-
|
|
Phosphodiesterase (PDE)
|
Metabolic Disease
|
|
PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .
|
-
-
- HY-125771S
-
|
18:0 Lyso-PC-d35; LPC(18:0)-d35
|
Isotope-Labeled Compounds
Endogenous Metabolite
HDAC
STAT
Apoptosis
|
Cancer
|
|
1-Stearoyl-sn-glycero-3-phosphocholine-d35 is deuterium labeled 1-Stearoyl-sn-glycero-3-phosphocholine (HY-125771). 1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
|
-
-
- HY-125783S3
-
-
-
- HY-107614G
-
|
1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium
|
LPL Receptor
ROCK
TGF-beta/Smad
TGF-β Receptor
|
Neurological Disease
Cancer
|
|
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .
|
-
-
- HY-125783R
-
|
16:0 Lyso PC (Standard)
|
Endogenous Metabolite
Reference Standards
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine (Standard) (16:0 Lyso PC (Standard)) is the analytical standard of 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). This product is intended for research and analytical applications. 1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
-
- HY-W140439S1
-
-
-
- HY-W140439R
-
-
-
- HY-157641A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
(2S)-18:1 Lyso PC is the (2S)-enantiomer of lysophosphatidylcholine (Lyso PC). LysoPC is a class of phospholipids, which are essential components of cell membranes.
|
-
-
- HY-120633
-
|
|
LPL Receptor
|
|
|
BMS-986104 is a potent and selective S1P1 receptor modulator. BMS-986104 is effective in a mouse EAE model, which is comparable to FTY720. Mechanistically, BMS-986104 exhibites excellent remyelinating effects on lysophosphatidylcholine (LPC)-induced demyelination in a three-dimensional brain cell culture assay.
|
-
-
- HY-173509
-
|
|
Phosphodiesterase (PDE)
LPL Receptor
|
Infection
Cardiovascular Disease
Neurological Disease
Cancer
|
|
ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer .
|
-
-
- HY-146925S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
|
|
15:0 Lyso PC-d5 is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
|
-
-
- HY-125783S2
-
-
-
- HY-125783S
-
-
-
- HY-146841S
-
|
1-Nonadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine-d5; 19:0 Lyso PC-d5
|
Isotope-Labeled Compounds
|
Others
|
|
Lecithin-cholesterol acyltransferase C19:0-d5 (19:0 lecithin-cholesterol acyltransferase-d5) is the deuterated form of lecithin-cholesterol acyltransferase C19:0 (HY-154830). Lecithin-cholesterol acyltransferase C19:0 is a lysophosphatidylcholine with a fully saturated C19 acyl chain. When lecithin-cholesterol acyltransferase C19:0 is combined with LPS (HY-D1056), it can induce the secretion of IL-1β by human monocyte-derived dendritic cells. Lecithin-cholesterol acyltransferase C19:0 can reduce the survival rate of dendritic cells derived from monocytes.
|
-
-
- HY-185237
-
-
-
- HY-113001
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
LysoPC (20:3 (8Z,11Z,14Z)/0:0) is a bioactive lysophosphatidylcholine. LysoPC (20:3 (8Z,11Z,14Z)/0:0) is applicable to research related to inflammation and autoimmune diseases .
|
-
-
- HY-164994
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
LysoPC (18:4(6Z,9Z,12Z,15Z)) is a lysophosphatidylcholine carrying stearidonic acid. LysoPC (18:4(6Z,9Z,12Z,15Z)) crosses the blood retinal barrier via the Mfsd2a transporter .
|
-
-
- HY-E70925
-
|
|
Phospholipase
|
Metabolic Disease
|
|
Lysophospholipase, Vibrio sp. (EC 3.1.1.5) is a catalytic enzyme with two substrates: 2-lysophosphatidylcholine and H2O, and two products: glycerophosphocholine and its carboxylate.
|
-
-
- HY-126233A
-
|
|
Phosphodiesterase (PDE)
|
Metabolic Disease
|
|
PAT-347 sodium is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .
|
-
-
- HY-113029
-
-
-
- HY-119601
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-107614G
-
|
1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium
|
Fluorescent Dyes
|
|
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .
|
| Cat. No. |
Product Name |
Type |
-
- HY-139414
-
|
|
Biochemical Assay Reagents
|
|
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .
|
-
- HY-125771
-
|
18:0 Lyso-PC; LPC(18:0)
|
Biochemical Assay Reagents
|
|
1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
|
-
- HY-W329357
-
|
|
Biochemical Assay Reagents
|
|
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .
|
-
- HY-107614G
-
|
1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium
|
Biochemical Assay Reagents
|
|
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1410
-
|
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
-
- HY-P1410A
-
|
|
TRP Channel
Piezo Channel
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 TFA also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 TFA is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N9410S
-
|
|
|
Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary
|
-
-
- HY-125783S1
-
|
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine-d31 (16:0 Lyso PC-d31) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
-
- HY-125771S
-
|
|
|
1-Stearoyl-sn-glycero-3-phosphocholine-d35 is deuterium labeled 1-Stearoyl-sn-glycero-3-phosphocholine (HY-125771). 1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
|
-
-
- HY-125783S3
-
|
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine-d9-1 (16:0 Lyso PC-d9-1) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
-
- HY-W140439S1
-
|
|
|
1-Oleoyl-sn-glycero-3-phosphocholine-d7 is deuterium labeled L-Alpha-Lysophosphatidylcholine,oleoyl.
|
-
-
- HY-146925S
-
|
|
|
15:0 Lyso PC-d5 is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
|
-
-
- HY-125783S2
-
|
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine-d49 (16:0 Lyso PC-d49) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
-
- HY-125783S
-
|
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine-d9 (16:0 Lyso PC-d9) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
-
- HY-146841S
-
|
|
|
Lecithin-cholesterol acyltransferase C19:0-d5 (19:0 lecithin-cholesterol acyltransferase-d5) is the deuterated form of lecithin-cholesterol acyltransferase C19:0 (HY-154830). Lecithin-cholesterol acyltransferase C19:0 is a lysophosphatidylcholine with a fully saturated C19 acyl chain. When lecithin-cholesterol acyltransferase C19:0 is combined with LPS (HY-D1056), it can induce the secretion of IL-1β by human monocyte-derived dendritic cells. Lecithin-cholesterol acyltransferase C19:0 can reduce the survival rate of dendritic cells derived from monocytes.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-125783
-
|
16:0 Lyso PC
|
|
Phospholipids
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
- HY-N9410
-
|
1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC(18:2/0:0); LysoPC(18:2)
|
|
Phospholipids
|
|
Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment .
|
-
- HY-125771
-
|
18:0 Lyso-PC; LPC(18:0)
|
|
Phospholipids
|
|
1-Stearoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine that inhibits HDAC3 activity and phosphorylation of STAT3 in K562 cells. 1-Stearoyl-sn-glycero-3-phosphocholine induces apoptosis and exhibits anticancer activity in chronic myelogenous leukemia (CML) K562 cells .
|
-
- HY-125783S
-
|
16:0 Lyso PC-d9
|
|
Phospholipids
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine-d9 (16:0 Lyso PC-d9) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
|
-
- HY-157694
-
|
|
|
Phospholipids
|
|
09:0 Lyso PC is a polar short-chain lysophosphatidylcholine.
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-107614G
-
|
1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium
|
LPL Receptor
ROCK
TGF-beta/Smad
TGF-β Receptor
|
Neurological Disease
Cancer
|
|
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
